160 results about "Env Protein" patented technology

Compositions, kits and methods for boosting, or for priming and boosting, high titer broadly neutralizing cross-clade antibody responses focused on single HIV-1 neutralizing epitopes are disclosed. gp120 DNA plasmids comprising HIV env genes are used to prime the antibody response. Primed subjects are immunized with recombinant fusion proteins that comprise a “carrier” protein fusion partner, preferably a truncated form of the MuLV gp70 Env protein, and a desired HIV neutralizing epitopes. Preferred epitopes are epitopes of V3 from one or more HIV clades. Immune sera from such immunized subjects neutralized primary isolates from virus strains heterologous to those from which the immunogens were constructed. Neutralizing activity was primarily due to V3-specific antibodies and cross-clade neutralizing Abs were present. This approach results in more potent and broader neutralizing antibody levels, a result of “immunofocusing” the humoral immune response on neutralizing epitopes such as V3.

The 28-kDa outer membrane proteins (P28) of Ehrlichia chaffeensis are encoded by a multigene family consisting of 21 members located in a 23-kb DNA fragment in the genome of E. chaffeensis. Fifteen of these proteins are claimed herein as novel sequences. The amino acid sequence identity of the various P28 proteins was 20-83%. Six of 10 tested p28 genes were actively transcribed in cell culture grown E. chaffeensis. RT-PCR also indicated that each of the p28 genes was monocistronic. These results suggest that the p28 genes are active genes and encode polymorphic forms of the P28 proteins. The P28s were also divergent among different isolates of E. chaffeensis. The large repertoire of the p28 genes in a single ehrlichial organism and antigenic diversity of the P28 among the isolates of E. chaffeensis suggest that the P28s may be involved in immune avoidance.

A protein from M. catarrhalis, designated the 74 kD protein, is isolated and purified. The 74 kD protein has an amino-terminal amino acid sequence which is conserved among various strains of M. catarrhalis. The protein has a molecular weight of approximately 74.9 kD as measured on a 10% SDS-PAGE gel, while its molecular weight as measured by mass spectrometry is approximately 74 kD. The 74 kD protein is used to prepare a vaccine composition which elicits a protective immune response in a mammalian host, to protect the host against disease caused by M. catarrhalis.

The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided.

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

The present invention provides recombinant viral particles for gene therapy and liposome compositions for drug delivery comprising an env protein of MMTV. The invention also provides retroviral or lentiviral env proteins comprising a mutation in a receptor-binding motif. The invention also provides nucleic acids, proteins, and compositions comprising the recombinant viral particles, nucleic acids, and proteins. The invention also provides methods for enhancing delivery of a gene or compound of interest to a target cell, and methods for targeting a compound of interest to an acidified compartment of a cell.

The invention discloses a method for using a machine learning technique for predicting outer membrane protein coded on genomes of germs. The method includes the steps of utilizing a PSI-BLAST algorithm to calculate a location specificity feature vector of the protein, adopting an autocorrelation function for conducting feature conversion, building a classification device based on a supporting vector machine, conducting classification on the outer membrane protein and non-outer membrane protein, receiving a protein sequence input by a user through a local computer program, and predicting whether or not the protein sequence belongs to the outer membrane protein. By means of the method, calculation prediction can be conducted on the protein sequence coded by the whole genome of the germs, thesensitivity is high, the calculation speed is high, and an effective tool is provided for fast identification and screening of inner and outer membrane protein of the genomes of the germs. The methodis an accurate and effective screening method for the outer membrane protein and can be widely applied to identification of the outer membrane protein of new sequencing genomes of germs.

The present invention provides artificial fusion proteins (AFPs) designed to elicit an anti-HIV immune response, as well as nucleic acid molecules and expression vectors encoding those proteins. The AFPs of the invention may comprise domains from various HIV proteins, such as Gag, Pol, Vif, and Env proteins, which are partial sequences. HIVCON is an AFP in which the HIV domains are from several HIV clade consensus sequences and which optionally contains additional domains which may be useful, for example, in monitoring expression levels or laboratory animal immune responses. Other aspects of the invention may include compositions and methods for inducing an anti-HIV immune response in a subject, preferably with a DNA prime-MVA boost strategy, and to induce a cell-mediated immune response.

Disclosed are peptides or a mixture of peptides, or analogs thereof, derived from the variable domains of the Chlamydia trachomatis (C. trachomatis) immunodominant major outer membrane protein (MOMP). The peptides or mixtures of peptides are characterized by having specificity only to C. trachomatis anti-MOMP antibodies and being non-cross reactive with anti-MOMP antibodies of other Chlamydia species Specific peptides are described (SEQ ID Nos. 1 to 8) as well as their analogs, which have essentially the same biological activity.

Consensus CHIKV E1 protein, consensus CHIKV E2 protein, consensus CHIKV capsid protein, or fragments and homologues thereof, and nucleic acid molecules that encode the same are disclosed. A consensus CHIKV Env protein which includes CHIKV E1 consensus protein, CHIKV E2 consensus protein, CHIKV E3 consensus protein, or fragments and homologues thereof and nucleic acid molecules that encode the same are also disclosed. Compositions and recombinant vaccines comprising CHIKV consensus proteins, and methods of using them are disclosed.

The invention discloses protein ompK subunit vaccine of assistant haemolysis vibrio extine and a preparation method thereof. The vaccine is PBS solution which converts the recombination protein of the coliform bacteria of recombination prokaryon expression plasmid pET30a-ompK expressed by inducing and after being purified; the concentration of the PBS solution is 0.25-0.5mg/ml. The method has the steps that: firstly, the extraction of an assistant haemolysis vibrio full gene group, the overall length of extine protein ompK DNA and the clone of a mature peptide coded sequence; secondly, the construction of a prokaryon expression plasmid of the ompK mature peptide coded sequence, thirdly, the obtaining way of the recombination ompK protein; fourthly, the detection to the immunity way and the immunity effect of a large yellow croaker with recombination ompK protein. The invention provides the preparation method of the assistant haemolysis vibrio ompK protein subunit vaccine, and simultaneously provides the detection method of the immunity effect of the large yellow croaker with recombination ompK protein, the preparation method is simple, and the usage is convenient.

Disclosed are a diagnosis method and a therapeutic method for cancer, both of which utilize HERV-H env gene and protein. Particularly, cancer can be diagnosed by detecting the expression of HERV-H env gene, and a reagent used for the detection of the expression can be used as a diagnosing agent. Cancer can be treated by inhibiting the function of HERV-H env gene, and a reagent used for the inhibition of the function can be used as an anti-cancer agent. Alternatively, cancer can be treated by administering a peptide having a specific sequence contained in HERV-H env protein or the like, and the peptide or the like can be used as a cancer vaccine.

The invention provides virus-like particles for pseudorabies virus. The virus-like particles consist of pseudorabies virus glycoprotein G and pseudorabies virus matrix protein M, and have stable and homogenous spatial structures; and the outer membrane protein of the virus-like particles contains all or partial fragments of the pseudorabies virus glycoprotein G, and can induce an organism to generate protective-level cellular immunity and humoral immunity. The virus-like particles do not comprise any nucleic acid component of chromosome of the pseudorabies virus, and avoid quality risks caused by inactivator addition. The virus-like particles can be conveniently purified by the conventional purification technology, and the quality risks possibly caused by inactivator addition in the traditional inactivated vaccines are avoided on principle. Meanwhile, due to a simple and quick construction and preparation mode, novel vaccines aiming at new strains can be conveniently and quickly designed and prepared. Based on the principle, novel polyvalent vaccines and multi-vaccines are easily formed on the basis of the particles; and the particles can widely replace related critical raw materials in the conventional practical technologies such as related antigen and antibody detection, functional protein vectors and the like.

The invention relates to a V. alginolyticus outer-membrane protein W gene, process for preparing the same and uses. The invention provides a novel V.alginolyticus OmpW gene, and the use of V.alginolyticus and Vibrio vulnficus OmpW protein and coded sequence, which comprises, linking purified nucleic acid sequence encoding protein active polypeptides having V.alginolyticus OmpW to expression regulation sequence, forming V.alginolyticus OmpW protein expression carrier, transferring the expression carrier into host cells, forming the recombination cells of the V.alginolyticus Omp protein, culturing the recombination cells and separating.

The invention provides a method of inducing an immune response against a human immunodeficiency virus (HIV) in a mammal. The method comprises administering to the mammal an adenoviral vector composition comprising one or more adenoviral vectors encoding two or more different HIV antigens, the production of which induces an immune response against HIV in the mammal. The invention also provides an adenoviral vector composition comprising four adenoviral vectors encoding an HIV clade A Env protein, an HIV clade B Env protein, an HIV clade C Env protein, and a fusion protein comprising an HIV clade B Gag protein and Pol protein, respectively.

The invention relates to preparation and application of a molecular adjuvant enhanced Asia 1 and A foot and mouth disease divalent vaccine. The vaccine comprises a molecular adjuvant interferon-alpha (IFN-alpha) polypeptide, a two-section T cell auxiliary antigenic epitope polypeptide, a six-section antigenic epitope polypeptide related to Asia 1 and A foot and mouth disease major outer membrane protein VP1 and VP2, and a killer T cell epitope polypeptide. The invention also relates to a preparation method and a using method for the vaccine. An animal experiment proves that the virus attack protective efficacy of the molecular adjuvant enhanced divalent foot and mouth disease protein engineering vaccine is obviously higher than that of a non-molecular adjuvant enhanced vaccine. By the recommended immunizing dose of the molecular adjuvant enhanced vaccine, a tested animal can resist attack of 10,000 median infective doses (ID50) of virulent Asia 1 and A foot and mouth disease virus, and the efficacy experiment also proves that the molecular adjuvant enhanced divalent vaccine for each animal at least contains 4 median protective doses (PD50).